Search Within

Naiyer A Rizvi

Formats
  1. Meeting Abstract (108)
  2. Journal Article (57)
  3. Research Letter (1)
Groups
  1. Department of Medicine (112)
  2. Solid Tumor Oncology Division (112)
  3. Thoracic Oncology (97)
  4. GSK Faculty (34)
  5. Department of Pathology and Laboratory Medicine (32)
  6. Radiology, Department of (30)

More Groups

People
  1. Mark Kris (71)
  2. Christopher Azzoli (37)
  3. Vincent Miller (37)
  4. Gregory Riely (30)
  5. Lee Krug (29)
  6. Matthew Hellmann (22)

More People

Years
  1. 2019 (1)
  2. 2018 (3)
  3. 2017 (6)
  4. 2016 (7)
  5. 2015 (18)
  6. 2014 (37)

More Years

Publications
  1. Journal of Clinical Oncology (65)
  2. Journal of Thoracic Oncology (28)
  3. Clinical Cancer Research (9)
  4. Annals of Oncology (8)
  5. International Journal of Radiation Oncology, Biology, Physics (8)
  6. Cancer Chemotherapy and Pharmacology (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (65)
  2. Elsevier Inc. (40)
  3. American Association for Cancer Research (13)
  4. Wiley Blackwell (10)
  5. Oxford University Press (8)
  6. Springer (8)

More Publishers

Results (166)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): Antitumor activity and association with tumor PD-L1 expression
    Meeting Abstract

    Gandhi, L.; Balmanoukian, A.; Hui, R. N.; Hamid, O.; Rizvi, N. A.; Leighl, N.; Gubens, M.; Goldman, J. W.; Lubiniecki, G. M.; Emancipator, K.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib
    Journal Article

    Hellmann, M. D.; Reva, B.; Yu, H.; Rusch, V. W.; Rizvi, N. A.; Kris, M. G.; Arcila, M. E.
    Journal of Thoracic Oncology (2014)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status in a phase 1 trial of nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Kluger, H.; Sznol, M.; Callahan, M.; Postow, M.; Gordon, R.; Segal, N. H.; Rizvi, N.; Lesokhin, A.; Atkins, M. B.; Kirkwood, J.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Smoking history and response to nivolumab in patients with advanced NSCLCS
    Meeting Abstract

    Hellmann, M. D.; Creelan, B. C.; Woo, K.; Sima, C. S.; Iams, W. T.; Antonia, S. J.; Horn, L.; Brahmer, J. R.; Gettinger, S.; Harbison, C.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Correlation of clinical activity of pembrolizumab (MK-3475) with immunohistochemical staining for programmed death-1 ligand (PD-L1) in ≥50% of tumor cells in a prospective non-small cell lung cancer (NSCLC) validation population
    Meeting Abstract

    Garon, E. G.; Rizvi, N. A.; LeighI, N. B.; Hui, R.; Eder, J. P.; Patnaik, A.; Aggarwal, C.; Horn, L.; Balmanoukian, A. S.; Gubens, M. A.; more...
    European Journal of Cancer (2014)

    Fulltext@MSK | Save
  • Classification of current anticancer immunotherapies
    Journal Article

    Galluzzi, L.; Vacchelli, E.; Bravo-San Pedro, J. M.; Buqué, A.; Senovilla, L.; Baracco, E. E.; Bloy, N.; Castoldi, F.; Abastado, J. P.; Agostinis, P.; more...
    Oncotarget (2014)

    Fulltext@MSK | Save
  • First-line monotherapy with nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and correlation of outcomes with PD-L1 status
    Meeting Abstract

    Rizvi, N. A.; Shepherd, F. A.; Antonia, S. J.; Brahmer, J. R.; Chow, L. Q.; Goldman, J.; Juergens, R.; Borghaei, H.; Ready, N. E.; Gerber, D. E.; more...
    International Journal of Radiation Oncology, Biology, Physics (2014)

    Fulltext@MSK | Save
  • Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) maintenance as monotherapy or in combination with bevacizumab (BEV) for non-small cell lung cancer (NSCLC) previously treated with chemotherapy
    Meeting Abstract

    Rizvi, N. A.; Antonia, S. J.; Shepherd, F. A.; Chow, L. Q.; Goldman, J.; Shen, Y.; Chen, A. C.; Gettinger, S.
    International Journal of Radiation Oncology, Biology, Physics (2014)

    Fulltext@MSK | Save
  • Phase II study of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced, refractory squamous non-small cell lung cancer
    Meeting Abstract

    Ramalingam, S. S.; Mazieres, J.; Planchard, D.; Stinchcombe, T. E.; Dy, G. K.; Antonia, S. J.; Horn, L.; Lena, H.; Minenza, E.; Mennecier, B.; more...
    International Journal of Radiation Oncology, Biology, Physics (2014)

    Fulltext@MSK | Save
  • Long-term survival, clinical activity, and safety of nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in patients (Pts) with advanced non-small cell lung cancer (NSCLC): Metastatic non-small cell lung cancer
    Meeting Abstract

    Gettinger, S. N.; Horn, L.; Gandhi, L.; Spigel, D. R.; Antonia, S. J.; Rizvi, N. A.; Powderly, J. D.; Heist, R. S.; Carvajal, R. D.; Jackman, D. M.; more...
    International Journal of Radiation Oncology, Biology, Physics (2014)

    Fulltext@MSK | Save